Clinical Trials
22 trialsNCT02883049 2026-05-04
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT00792948 2026-04-13
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT00278408 2025-08-26
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
Universität des Saarlandes
Phase 3 Completed
NCT00001337 2025-06-22
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02420717 2025-06-08
Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01184885 2025-05-04
A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy
Thomas Jefferson University
Phase EARLY_PHASE1 Completed
NCT03488225 2024-07-16
Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04933617 2024-07-09
Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT02199184 2024-06-11
Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00039130 2023-08-21
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01092182 2023-04-27
Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02481310 2022-02-21
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
Northwestern University
Phase 1/2 Unknown
NCT00070018 2022-01-11
S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
SWOG Cancer Research Network
Phase 2 Completed
NCT01363128 2021-05-03
Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00075725 2021-04-27
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
Children's Oncology Group
Phase 3 Completed
NCT00671034 2021-04-27
Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
Children's Oncology Group
Phase 3 Completed
NCT00866307 2021-04-27
Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011)
Children's Oncology Group
Phase 1 Completed
NCT00004031 2021-02-02
SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
SWOG Cancer Research Network
Phase 3 Completed
NCT00392834 2018-06-06
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma
AIDS Malignancy Consortium
Phase 2 Completed
NCT00669877 2018-05-16
Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00057811 2014-09-19
Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma
Children's Oncology Group
Phase 2 Completed
NCT00126191 2013-05-23
Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma
Dana-Farber Cancer Institute
Phase 2 Terminated